Jain Global’s Protagonist Therapeutics PTGX Stock Holding History

Jain Global’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,850	Closed	-$1.12M	–	1560
2025 Q4	$1.12M	Sell	12,850 -2,000	-13%	-$164K	0.01%	696
2025 Q3	$986K	Buy	+14,850	New	+$844K	﹤0.01%	651
2025 Q2	–	Sell	-24,867	Closed	-$1.2M	–	1541
2025 Q1	$1.2M	Buy	+24,867	New	+$1.04M	0.01%	424

Other funds holding PTGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Jain Global's PTGX Position: Q1 2026 in Review

Jain Global sold out of Protagonist Therapeutics (PTGX) in Q1 2026, closing a stake of 12,850 shares — an estimated $1.12M sold.

Jain Global first reported a position in PTGX in Q1 2025 and held it in 3 quarters. The position peaked at $1.2M in Q1 2025. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

Jain Global reported no remaining Protagonist Therapeutics position as of Q1 2026 after selling out during the quarter.
Jain Global sold 12,850 Protagonist Therapeutics shares in Q1 2026, an estimated $1.12M.
Jain Global first reported a position in Protagonist Therapeutics in Q1 2025 and held it in 3 quarters.
Jain Global's Protagonist Therapeutics position peaked at $1.2M in Q1 2025.
317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Jain Global's 13F filing for Q1 2026, filed 15 May 2026.